Scientists determine why some patients don’t respond well to wet macular degeneration treatment, show how new experimental drug can bridge gap
**EMBARGOED FOR RELEASE UNTIL NOV. 4 AT 3:00 P.M. EST**
A new study from researchers at Wilmer Eye Institute, Johns Hopkins Medicine explains not only why some patients with wet age-related macular degeneration (or “wet” AMD) fail to have vision improvement with treatment, but also how an experimental drug could be used with existing wet AMD treatments to save vision.
Wet AMD, one of two kinds of AMD, is a progressive eye condition caused by an overgrowth of blood vessels in the retina, the light-sensing tissue in ...














